Lipid lowering effects and safety of evolocumab in Chinese patients at very high cardiovascular risk:a single-center study

作     者：Meng Chai Haitao Zhang Lixia Yang Jing Liang Hongya Han Xiaoli Liu Xiaoteng Ma Yan Liu Dongmei Shi Yingxin Zhao Yuyang Liu Yujie Zhou 

作者机构：Department of CardiologyBeijing Anzhen HospitalCapital Medical UniversityBeijing Institute of Heart Lung and Blood Vessel DiseaseBeijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic DiseaseClinical Center for Coronary Heart DiseaseCapital Medical UniversityBeijing 100029China Department of CardiologyAir Force Medical CenterBeijing 100142China 

出 版 物：《Chinese Medical Journal》 (中华医学杂志（英文版）)

年 卷 期：2023年第136卷第11期

页      面：1358-1360页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

基　　金：National Key Research and Development Program of China(No.2017YFC0908800) Beijing Municipal Administration of Hospitals’Mission plan(No.SML20180601) 

主　　题：patients Lipid cardiovascular 

摘      要：Low-density lipoprotein cholesterol(LDL-C)is an independent risk factor for atherosclerotic cardiovascular disease(ASCVD).Even after lipid-lowering therapy(LLT)with statins or statin–ezetimibe,a large proportion of patients at very high risk still do not reach the LDL-C targets(1.4 mmol/L and≥50%reduction).[1,2]Proprotein convertase subtilisin/kexin type 9 inhibitor(PCSK9i)is recommended for patients at high or very high cardiovascular risk inwhom LDL-C reduction is not adequate with statin therapy or in those with statin *** data are available regarding the use of PCSK9i in China.